Global Dementia and Movement Disorders Market Size, Share, Growth Analysis Report - Forecast 2034

Industry Prospective:

The global dementia and movement disorders market size was worth around USD 9.19 Billion in 2024 and is predicted to grow to around USD 17.66 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 7.5% between 2025 and 2034. The report analyzes the global dementia and movement disorders market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the dementia and movement disorders industry.

Request Free Sample

Dementia and Movement Disorders Market: Overview

Dementia is a broad spectrum of mental diseases that, over time, cause a person's capacity for thought and memory to decrease. The causes of dementia have not yet been discovered, despite advances in science and medicine. As a result, the illness is solely managed on a symptomatic basis. However, it is well established that numerous movement disorders, including Parkinson's, can trigger dementia. They can happen to anyone of any age, from newborns to the elderly. While symptoms in some cases are limited to issues with motor control, in others they can also impact cognitive and autonomic processes.

The market share growth by the movement disorders segment will be significant during the forecast period. Movement disorders refer to a group of neurological conditions that primarily affect a person's ability to produce and control movements. Movement disorders can significantly impact an individual's ability to perform daily activities and lead a fulfilling life. Effective medications that can manage symptoms and enhance functional abilities are in demand to improve the quality of life for those affected.

Key Insights

• As per the analysis shared by our research analyst, the global dementia and movement disorders market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2025-2034).
• Regarding revenue, the global dementia and movement disorders market size was valued at around USD 9.19 Billion in 2024 and is projected to reach USD 17.66 Billion by 2034.
• The dementia and movement disorders market is projected to grow at a significant rate due to rising prevalence of neurodegenerative diseases, advancements in diagnostic technologies, and increasing R&D for novel therapeutics.
• Based on Type, the Progressive Dementia segment is expected to lead the global market.
• On the basis of Drug Class,, the Glutamate inhibitors segment is growing at a high rate and will continue to dominate the global market.
• Based on the Route of Administration, the Parenteral segment is projected to swipe the largest market share.
• By End-Use, the Hospitals segment is expected to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Dementia and Movement Disorders Market: Growth Drivers

Rising geriatric population to fuel the market expansion.

The rising geriatric population is one of the main factors promoting the growth of global dementia and movement disorders market. Children under the age of five have been outnumbered by persons 60 years and older in the year 2020. Eighty percent of the world's elderly population will reside in low- and middle-income nations by 2050. On an account of this, it is anticipated that there would be 78 million cases of dementia worldwide by 2030 and 139 million cases by 2050. Globally rising senior populations will raise the likelihood that people may have neurological conditions like dementia, which will increase demand for dementia medications and propel the market.

Dementia and Movement Disorders Market: Restraints

High costs associated with the treatment to hamper the market growth

The growing financial burden of neurological illnesses is one of the main reasons impeding the market's expansion for treatments for dementia and movement disorders. One of the 10 major leading causes of mortality in the US, according to the CDC, is Alzheimer's disease. As a result, the US has a significant need for Alzheimer's disease treatment. Patients in the US, however, face difficulties as a result of rising treatment expenses. The Michael J. Fox Foundation and other national organizations in the US completed and released research titled The Economic Burden of Parkinson's Disease. According to the report, Parkinson's disease costs the US government, families, and people a total of $51.9 billion every year. Thus, high costs and increasing economic burden are the factors hindering the growth of global market.

Dementia and Movement Disorders Market: Opportunities

Heavy investments in R&D activities to foster market expansion during the forecast period

Dementia correlated with Alzheimer's disease is anticipated to see growth over the course of the forecast period as a result of increasing disease-modifying therapeutic R&D activities and increased investments by major players in clinical trials of cutting-edge treatment alternatives. In addition to this, mergers and acquisitions as well strategic collaborations by big pharma for business expansion are also likely to generate numerous opportunities for the growth of global dementia and movement disorders market during the forecast period.

Dementia and Movement Disorders Market: Challenges

Stringent regulatory framework to act as a challenge to market growth

Even though there is a lot of work being done to help those with dementia and movement disorders, the market is facing profound challenges due to the regulatory framework's strictness, the lengthy approval process for drugs, the lack of funding for research & development, and the inadequate therapeutic management techniques. Additionally, the majority of disease-treatment medications fail Phase III testing, rendering efforts futile and reverting the issue of treating these disorders to its original state.

Dementia and Movement Disorders Market: Segmentation

The global dementia and movement disorders market is categorized based on type, drug class, route of administration, end use, and region.

Based on Type, the global dementia and movement disorders market is divided into Progressive Dementia, Movement Disorder, and Other Neurological Abnormalities.

On the basis of Drug Class,, the global dementia and movement disorders market is bifurcated into Glutamate inhibitors, acetylcholinesterase inhibitors, MAO inhibitors, and Others.

By Route of Administration, the global dementia and movement disorders market is split into Parenteral and Oral.

In terms of End-Use, the global dementia and movement disorders market is categorized into Hospitals, Clinics, and Others.

Dementia and Movement Disorders Market: Report Scope

Dementia and Movement Disorders Market: Regional Landscape

North America to dominate the global market during the forecast period

Among the regions, North America is estimated to lead global dementia and movement disorders market. During the projection period, North America will account for 48% of market growth. The largest market in North America for the treatment of dementia and movement disorders are the US and Canada. Compared to the rest of the world, this region's market will increase more rapidly. Over the projection period, dementia and movement disorder therapy market would rise in North America due to the rising incidence of target illnesses including Parkinson's disease and Alzheimer's disease. On the other hand, due to government financial backing for enhancing quality healthcare infrastructure in numerous countries throughout the region and the intensifying campaigns for promoting consciousness of the therapies for dementia and movement disorders, the treatment procedures, and their effect on mental health, Asia Pacific may also present enormous opportunities for the market growth during the forecast period.

Recent Developments

• In June 2022, in order to create and market AL01811, a new preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease-modifying therapy for Parkinson's disease patients, Biogen and Alectos Therapeutics have engaged in a licensing and partnership agreement. Through this partnership, Biogen's ability to create treatments for movement disorders will be combined with Alectos' expertise in small-molecule therapies.
• In July 2021, GSK and Alector announced a strategic collaboration to produce progranulin-elevating monoclonal antibodies, AL001 and AL101, for a variety of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia.

Dementia and Movement Disorders Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the dementia and movement disorders market on a global and regional basis.

The global dementia and movement disorders market is dominated by players like:

• Novartis AG
• Merck and Co. Inc.
• Biogen Inc.
• Bausch Health Companies Inc.
• Acorda Therapeutics Inc.
• AbbVie Inc.
• Johnson and Johnson
• GlaxoSmithKline Plc
• Eisai Co. Ltd.
• Teva Pharmaceutical Industries Ltd

The global dementia and movement disorders market is segmented as follows:

By Type

• Progressive Dementia
• Movement Disorder
• Other Neurological Abnormalities

By Drug Class,

• Glutamate inhibitors
• acetylcholinesterase inhibitors
• MAO inhibitors
• Others

By Route of Administration

• Parenteral
• Oral

By End-Use

• Hospitals
• Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America